MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2025 International Congress

    Long-Term Therapeutic Effect of Botulinum Neurotoxin Type A (BoNT-A) in Cervical Dystonia: A Case Series.

    R. Lopez-Castellanos, R. Lopez-Contreras (Boston, USA)

    Objective: To evaluate the long-term therapeutic effect of Botulinum neurotoxin type A (BoNT-A) in cervical dystonia. Background: Cervical dystonia is the most common adult-onset focal…
  • 2025 International Congress

    Development and Testing of a Smartphone Application to Capture Patient-Centered Outcome (PCO) Measures for Dystonia

    P. Reyes, A. Tingin, B. Berman, S. Schneider, J. Hieshetter, K. Kuman, G. Kilic-Berkmen, L. Wright, F. Qeadan, J. Perlmutter, H. Jinnah, S. Pirio-Richardson (Richmond, USA)

    Objective: Develop a smartphone application to collect patient-centered outcome (PCO) measures for dystonia. Background: PCO measures tailored for each major adult-onset focal dystonia subtype (Cervical…
  • 2025 International Congress

    Characteristics of IncobotulinumtoxinA Treatment for Cervical Dystonia in a Real-World Setting: Dosing and Muscles Injected

    J. Holmes, A. Kong, G. Askin, D. Nomah, D. Joseph, K. Biney, M. Hast (Raleigh, USA)

    Objective: To describe incobotulinumtoxinA doses and muscles injected in a real-world setting for patients with cervical dystonia (CD) Background: IncobotulinumtoxinA is approved to treat CD…
  • 2025 International Congress

    Blepharospasm as cause of facial pain and “sinus” headache: A case series

    J. Anang (Winnipeg, Canada)

    Objective: Describe the clinical spectrum of blepharospasm Background: Blepharospasm is characterized by stereotyped, bilateral and synchronous spasms of the orbicularis oculi muscles Method: Case report…
  • 2024 International Congress

    Tardive Dystonia Following Risperidone Treatment : A Case Report and Therapeutic Approach

    M. Hildaria, D. Tunjungsari, A. Tiksnadi (Central Jakarta, Indonesia)

    Objective: To report a case of tardive dystonia induced by risperidone and discuss the therapeutic approach, including the use of botulinum toxin. Background: Risperidone, a…
  • 2024 International Congress

    Disparities in Botulinum Toxin Utilization for Cervical Dystonia in a United States Medicare Population

    M. Verduzco-Gutierrez, A. Keener, I. Howard, D. Torres-Russotto, J. Sparrow, R. Kazerooni (San Antonio, USA)

    Objective: To examine the disparities in utilization of botulinum toxin (BoNT) injections for patients with cervical dystonia (CD) within the United States Medicare population. Background:…
  • 2024 International Congress

    Perceptions of Diseases in Patients with Cervical Dystonia

    D. Talkington, D. Sblendorio, K. Pyle, M. Coleman, M. Patel, M. Moreno-Escobar, A. Murray, A. Memon, J. Frey (Morgantown, USA)

    Objective: To explore how perception of disease can impact stigma, mood, quality of life, and severity of symptoms in patients with cervical dystonia (CD). Background:…
  • 2024 International Congress

    Botulinum Toxin and Deep Brain Stimulation in Dystonia

    J. Souza, A. Falcone, R. Barbosa, M. Soares, R. Munhoz, M. Farah, T. Capato, S. Casagrande, M. Cordellini, G. Micheli, J. Limongi, E. Barbosa, C. Listik, R. Cury (Sao Paulo, Brazil)

    Objective: The primary outcome was the relationship between BoNT dosage and DBS surgery in each muscle. A secondary analysis of BoNT dosages through different muscle…
  • 2024 International Congress

    Do Lower Doses of Botulinum Neurotoxin Type-A Offer a Longer Duration of Effect and Superior Efficacy in Patients with Cervical Dystonia?

    A. Kundrick, H. Fernandez (Cleveland, USA)

    Objective: To determine if there is a difference in efficacy and duration of effect between high-dose and low-dose botulinumtoxin neurotoxin type-A for cervical dystonia. Background:…
  • 2024 International Congress

    Efficacy Remaining at Time of Requested Retreatment Following Botulinum Toxin Treatment for Cervical Dystonia: Potential for a New Treatment Paradigm with DaxibotulinumtoxinA

    A. Ellenbogen, R. Hauser, A. Patel, P. Mcallister, D. Vitarella, T. Gross, R. Kazerooni, C. Gallagher, D. Hollander (Farmington Hills, USA)

    Objective: To assess the residual therapeutic efficacy of prior botulinum toxin (BoNT) injection at the patient-desired retreatment interval in cervical dystonia (CD). Background: BoNT injections…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 21
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley